side‐effects ‐ side‐effects causing abandon · prevention of reintubation
The review found no eligible studies for this question.
2 findings from 1 review
Intervention not reported
Hypotension requiring medical therapy (vasopressors or fluid boluses), occurring during the procedure No. of participants: 124(1 RCT) · Procedural pain in neonates
It is very uncertain whether the intervention changes hypotension requiring medical therapy (vasopressors or fluid… (very low certainty).
1 finding from 1 review
RR 5.53 [0.27, 112.3]
Studies not reported
Very low
Hypotension requiring medical therapy (vasopressors or fluid boluses), occurring during the procedure · procedural pain in neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Renal replacement therapy · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
B4: Discontinuation of therapy due to maternal adverse effects – an all women · the woman
1 finding from 1 review
Proportion of participants in which at least 1 conduction block resolved after therapy · people with multifocal motor neuropathy
IVIg showed no clear difference in proportion of participants in which at least 1 conduction block… compared with placebo (low certainty).
1 finding from 1 review
RR 7 [0.95, 51.7]
28 participants
Low
Maternal adverse effects of therapy · women at risk of preterm birth
Dexamethasone showed no clear difference in maternal adverse effects of therapy compared with betamethasone – maternal outcomes (moderate certainty).
1 finding from 1 review
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review